Details for Patent: 10,662,160

Which drugs does patent 10,662,160 protect, and when does it expire?

Patent 10,662,160 protects ORLADEYO and is included in two NDAs.

Protection for ORLADEYO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-four patent family members in twenty-one countries.

Summary for Patent: 10,662,160

Title:	Crystalline salts of a plasma kallikrein inhibitor
Abstract:	Disclosed are crystalline salts of Compound I, methods of preparing them, and related pharmaceutical preparations thereof. Also disclosed are methods of treatment using the crystalline salts of the invention.
Inventor(s):	Yahya El-Kattan, Yarlagadda S. Babu
Assignee:	Athyrium Opportunities Iii Co Invest 1 Lp
Application Number:	US16/671,649
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,662,160
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 10,662,160

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Biocryst	ORLADEYO	berotralstat dihydrochloride	CAPSULE;ORAL	214094-001	Dec 3, 2020		RX	Yes	No					Y
Biocryst	ORLADEYO	berotralstat dihydrochloride	CAPSULE;ORAL	214094-002	Dec 3, 2020		RX	Yes	Yes					Y
Biocryst	ORLADEYO	berotralstat dihydrochloride	PELLETS;ORAL	219776-001	Dec 11, 2025		RX	Yes	No					Y

International Family Members for US Patent 10,662,160

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	116951
Australia	2019374115
Brazil	112021008249